Merck & Co. launched a multi-target discovery collaboration and license agreement with Protillion Biosciences, setting up new AI-discovered therapeutic candidates built on Protillion’s Prot-MaP on-chip antibody discovery platform. The program combines Merck’s drug discovery expertise with Protillion’s “lab-in-the-loop” workflow that ties AI design iterations to quantitative wet-lab binding data.